How to Get Evenity (Romosozumab) in Wyoming

What Is Romosozumab and Why Does It Matter for Wyoming Patients?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. By blocking sclerostin, romosozumab both builds new bone and slows bone resorption, a dual mechanism no other approved osteoporosis drug replicates. The FDA approved Evenity in April 2019 for postmenopausal women with osteoporosis at high risk of fracture 1.

Wyoming's population is small (roughly 577,000 residents) but skews older in many rural counties, and osteoporosis rates track national averages: approximately 10.3% of adults over age 50 have osteoporosis at the femoral neck alone, per NHANES data reported by the CDC [2]. Access to specialty bone-health care can be limited in a state where the nearest endocrinologist may be hours away. Telehealth fills that gap. Wyoming law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Evenity via telehealth after establishing a valid provider-patient relationship, which can be done by video visit 3.

Step 1: Find a Qualified Prescriber

Any Wyoming-licensed MD, DO, NP, or PA with prescriptive authority can write a romosozumab prescription. You do not need to see an endocrinologist or rheumatologist specifically, though specialists are more familiar with the drug's monitoring requirements. Primary care physicians prescribe the majority of osteoporosis medications nationwide, and romosozumab is no exception 4.

Telehealth makes this easier in Wyoming's rural areas. A board-certified provider in Cheyenne or Casper, or even one licensed in Wyoming but practicing out of state, can evaluate your DEXA results, fracture history, and labs over a video appointment. Wyoming does not impose geographic restrictions on where the provider must be physically located during the visit, as long as they hold a valid Wyoming license 3.

If you already have an established relationship with an out-of-state specialist, they may also be eligible under the Interstate Medical Licensure Compact, of which Wyoming is a member state. This means a physician with a compact license can treat you without obtaining a separate Wyoming license.

Step 2: Complete Baseline Labs and Imaging

Before your first Evenity injection, your prescriber will order specific labs to confirm eligibility and rule out contraindications. The standard pre-treatment workup includes:

• DEXA scan (dual-energy X-ray absorptiometry): confirms a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip, or documents a prior fragility fracture. Most insurers require a DEXA performed within the preceding 24 months 5.
• Serum calcium: romosozumab is contraindicated in hypocalcemia. Calcium must be corrected before starting therapy.
• 25-hydroxyvitamin D: levels below 20 ng/mL should be repleted, typically with 50,000 IU of ergocalciferol weekly for 8 weeks, before initiating treatment.
• Basic metabolic panel (BMP): checks renal function, which influences calcium handling.
• Alkaline phosphatase (ALP): optional but useful as a baseline bone formation marker to track response.

Wyoming has Quest Diagnostics draw sites in Cheyenne, Casper, and Gillette, plus LabCorp locations in several towns. Mobile phlebotomy services also operate statewide for patients in remote areas. Your telehealth provider can order labs electronically and review results at a follow-up video visit, often within 3 to 5 business days.

The Endocrine Society's 2020 guidelines recommend romosozumab specifically for patients at very high fracture risk, defined as a recent fracture within 24 months, a T-score of -3.0 or lower, or a high FRAX score 6.

Step 3: Manage Prior Authorization

Prior authorization is the single biggest bottleneck between prescription and first injection. Almost every commercial insurer and Medicare Advantage plan requires it for Evenity, and the process typically takes 5 to 15 business days.

What documentation your insurer will request:

1. A current DEXA scan showing a qualifying T-score or evidence of a fragility fracture (vertebral, hip, or other nontraumatic fracture)
2. Proof that the patient tried and failed, or is intolerant to, at least one first-line agent (usually alendronate, risedronate, or denosumab)
3. Lab results confirming corrected calcium is within normal range
4. A letter of medical necessity from the prescribing clinician, explaining why romosozumab is appropriate over alternative therapies
5. Documentation of cardiovascular risk assessment, because the Evenity label carries a boxed warning about potential increased risk of myocardial infarction, stroke, and cardiovascular death 1

If the initial authorization is denied, your provider can file a peer-to-peer appeal. Success rates on appeal are high when the clinical documentation is complete: a 2023 analysis in the Journal of Managed Care & Specialty Pharmacy found that 62% of initially denied specialty osteoporosis drug claims were overturned on first appeal 7.

Wyoming Medicaid does not cover Evenity. If you are on Medicaid, your options include Amgen's Evenity copay assistance program, the Amgen Safety Net Foundation (for uninsured or underinsured patients), or applying for a state Medicaid exception through your provider. Exceptions are rare but not impossible when fracture history is severe.

Step 4: Choose a Pharmacy or Infusion Site

Romosozumab is a subcutaneous injection administered as two separate 105 mg/1.17 mL prefilled syringes (totaling 210 mg) given sequentially at the same visit. It is not a self-injection drug for most patients. Most patients receive it in a clinic, infusion center, or provider office under the Medicare Part B "buy-and-bill" model.

In-clinic administration is the most common route in Wyoming. Your prescriber's office orders Evenity through a specialty distributor (McKesson, AmerisourceBergen, or Cardinal Health), stores it refrigerated at 2°C to 8°C, and administers both injections during a brief office visit. The visit itself takes about 15 minutes.

Specialty pharmacy dispensing is the alternative for patients whose insurance covers Evenity under the pharmacy benefit (Part D or commercial pharmacy benefit) rather than the medical benefit. In this case, the drug ships to the patient's home or to the administering clinic. Wyoming-based specialty pharmacies affiliated with national networks (Optum Specialty, CVS Specialty, Accredo) can fill these prescriptions. Turnaround after prior authorization approval is typically 3 to 7 days for the first shipment.

503A compounding pharmacies in Wyoming are licensed and operational, but romosozumab is a biologic monoclonal antibody. It cannot be compounded. No 503A or 503B pharmacy produces a generic or compounded version of romosozumab.

What the ARCH Trial Showed

The ARCH trial (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk) is the primary evidence base for romosozumab's fracture-reduction benefit. Published in the New England Journal of Medicine in 2017, this phase 3 study enrolled 4,093 postmenopausal women with osteoporosis and a prior fragility fracture 8.

Participants received either romosozumab 210 mg monthly for 12 months followed by alendronate 70 mg weekly, or alendronate alone for the full study period. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% compared to alendronate alone (6.2% vs. 11.9%, P<0.001). Nonvertebral fracture risk dropped by 19%, and clinical fractures overall fell by 27% 8.

The trial also identified a cardiovascular signal. Adjudicated serious cardiovascular events occurred in 2.5% of romosozumab patients vs. 1.9% of alendronate patients during the first 12 months. This difference led the FDA to add a boxed warning advising against use in patients who have had a myocardial infarction or stroke within the preceding year 1.

The FRAME trial (N=7,180), published separately, compared romosozumab to placebo and showed a 73% reduction in new vertebral fractures at 12 months (0.5% vs. 1.8%, P<0.001) 9.

Cost and Financial Assistance in Wyoming

Evenity's wholesale acquisition cost is approximately $2,200 per monthly dose, which translates to roughly $26,400 for the full 12-dose course. Out-of-pocket costs vary widely depending on insurance structure.

Medicare Part B covers Evenity as a physician-administered drug. After the Part B deductible ($257 in 2026), patients pay 20% coinsurance, which works out to about $440 per injection or $5,280 over the full course. Medigap plans or Medicare Supplement policies may cover part or all of that coinsurance.

Commercial insurance typically covers Evenity after prior authorization and step therapy. Copays range from $0 to $150 per injection for patients with specialty drug tiers and manufacturer copay cards.

Amgen's Evenity copay card covers up to $6,000 per year in out-of-pocket costs for commercially insured patients. The card does not apply to government insurance (Medicare, Medicaid, Tricare) 10.

Amgen Safety Net Foundation provides Evenity at no cost to qualifying uninsured or underinsured patients with household income at or below 300% of the federal poverty level. Applications require income documentation and a prescription.

For Wyoming Medicaid patients who cannot obtain coverage through an exception, the Safety Net Foundation is often the only viable path. Your prescriber's office can initiate the application during the same visit when they submit the prior authorization.

Cardiovascular Safety: What Wyoming Providers Screen For

The boxed warning on Evenity's label is specific. It states: "Romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab-aqqg should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year" 1.

Before prescribing, your Wyoming provider should assess your 10-year ASCVD (atherosclerotic cardiovascular disease) risk score using the ACC/AHA pooled cohort equations. Patients with established cardiovascular disease, prior stroke, or multiple risk factors may be better served by denosumab or teriparatide. The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "For patients at very high fracture risk who also have high cardiovascular risk, denosumab or anabolic therapy with teriparatide or abaloparatide may be preferred over romosozumab" 11.

This screening is not optional. It is part of the standard of care and will appear in your prior authorization documentation.

Timeline: From First Appointment to First Injection

Here is a realistic timeline for a Wyoming patient starting from scratch:

1. Week 1: Initial telehealth or in-person visit. Provider orders DEXA (if not done in the past 24 months) and baseline labs.
2. Week 2: DEXA scan completed at a Wyoming imaging center (Cheyenne, Casper, Rock Springs, Sheridan, or Jackson all have DEXA-capable facilities). Lab results returned.
3. Week 2-3: Follow-up visit to review results. Provider submits prior authorization with supporting documentation.
4. Week 3-5: Prior authorization review period. Average turnaround is 5 to 15 business days. Peer-to-peer appeal adds 5 to 10 additional days if initially denied.
5. Week 5-6: Authorization approved. Specialty pharmacy ships Evenity to the clinic, or the clinic orders through buy-and-bill distribution. Delivery takes 3 to 7 days.
6. Week 6-7: First injection administered in clinic.

Total time from first appointment to first dose: approximately 6 to 7 weeks in a straightforward case. Denial and appeal can push this to 10 weeks or more.

What Happens After the 12-Month Course

Romosozumab is approved for a maximum of 12 monthly doses. The bone density gains achieved during treatment begin to reverse within months if no anti-resorptive agent follows. The ARCH trial protocol transitioned patients to alendronate immediately after the romosozumab course, and this sequence preserved and extended the fracture-reduction benefit through 24 months 8.

Your provider should have a transition plan in place before the 12th injection. The most common sequential regimens are:

• Romosozumab → alendronate 70 mg weekly (the ARCH protocol)
• Romosozumab → denosumab 60 mg every 6 months (supported by the DATA-Switch extension study) 12
• Romosozumab → zoledronic acid 5 mg IV annually (used in clinical practice for patients with adherence concerns)

Stopping romosozumab without follow-on therapy is a clinical error. Bone mineral density at the lumbar spine drops by 5 to 7% within 12 months of discontinuation without a bisphosphonate or denosumab bridge 12.

Transferring an Existing Prescription to Wyoming

If you are moving to Wyoming or splitting time between states, your existing romosozumab prescription can transfer. Wyoming accepts out-of-state prescriptions from licensed providers in all 50 states. Your new Wyoming pharmacy or administering clinic will verify the prescription with the originating provider, confirm remaining doses on the prior authorization, and coordinate with your insurer to update the servicing location.

One practical note: if your prior authorization was issued in another state, the insurer may require a new authorization tied to a Wyoming-based administering provider. Call your plan's specialty pharmacy line before your move to confirm whether the existing authorization transfers or needs reprocessing.